Inferra AI / Company / PTGX
Protagonist Therapeutics, Inc.
PTGX · Health Care
Last earnings Aug 5, 2026
Key results
Revenuequarter
$5.5 million
revenue of $5.5 million and $4.2 million for the second quarter of 2025 and 2024, respectively, was comprised of development services we provided under the Takeda collaboration agreement.
SEC original ↗Protagonist Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
License and collaboration revenue of $33.9 million for the six months ended June 30, 2025 was comprised of (i) proportional recognition of a $25 million milestone earned from Takeda in Q1 25, and (ii) development services we provided during the period.
SEC original ↗Protagonist Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
revenue of $259.1 million for the six months ended June 30, 2024 included (i) $254.1 million of the $300.0 million initial transaction price for the Takeda collaboration agreement allocated to the rusfertide license upon effectiveness of the agreement, and (ii) development services we provided during the period.
SEC original ↗Protagonist Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Net incomequarter
$176.7 million
net income of $176.7 million, or $2.89 per basic share and $2.77 per diluted share, for the six months ended June 30, 2024, which included recognition of $259.1 million revenue related to the Takeda collaboration agreement upfront payment of $300.0 million.
SEC original ↗Protagonist Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q2 2025 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $5.5 million | — | — |
| Net income | $176.7 million | — | — |
Guidance · company-stated
No guidance located in the held release
Capital allocation
Stock-based compensation expense associated with stock options is based on the estimated grant date fair value using the Black-Scholes valuation model, which requires the use of assumptions related to expected stock price volatility, option term, risk-free interest rate and dividend yield.
Treasury and agency securities 271,722 271,722 Commercial paper 294,306 294,306 Corporate debt securities 77,122 77,122 Total financial assets $ 124,167 $ 663,056 $ $ 787,223 13 Table of Contents December 31, 2025 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 40,774 $ $ $ 40,774 Certificates of deposit 11,391 11,391 U.
Event summary
Protagonist Therapeutics, Inc. Q2 2025 — revenue of $5.5 million and $4.2 million for the second quarter of 2025 and 2024, respectively, was comprised of development services we provided under the Takeda collaboration agreement.
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Stock-based compensation expense associated with stock options is based on the estimated grant date fair value using the Black-Scholes valuation model, which requires the use of assumptions related to expected stock price volatility, option term, risk-free interest rate and dividend yield.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Treasury and agency securities 271,722 271,722 Commercial paper 294,306 294,306 Corporate debt securities 77,122 77,122 Total financial assets $ 124,167 $ 663,056 $ $ 787,223 13 Table of Contents December 31, 2025 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 40,774 $ $ $ 40,774 Certificates of deposit 11,391 11,391 U.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Treasury and agency securities 348,948 348,948 Commercial paper 77,865 77,865 Corporate debt securities 159,211 159,211 Total financial assets $ 40,774 $ 597,415 $ $ 638,189 The Company s certificates of deposit, U.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Treasury bills, commercial paper and corporate debt securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques, for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Treasury and agency securities 272,197 26 ( 501 ) 271,722 Commercial paper 294,401 1 ( 96 ) 294,306 Corporate debt securities 77,226 1 ( 105 ) 77,122 Total cash equivalents and marketable securities $ 787,909 $ 28 $ ( 714 ) $ 787,223 Classified as: Cash equivalents $ 357,850 Marketable securities - current 362,498 Marketable securities - noncurrent 66,875 Total cash equivalents and marketable securities $ 787,223 December 31, 2025 Amortized Gross Unrealized Cost Gains Losses Fair Value Money market funds $ 40,774 $ $ $ 40,774 Certificates of deposit 11,387 4 11,391 U.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Treasury and agency securities 348,250 706 ( 8 ) 348,948 Commercial paper 77,868 4 ( 7 ) 77,865 Corporate debt securities 159,127 93 ( 9 ) 159,211 Total cash equivalents and marketable securities $ 637,406 $ 807 $ ( 24 ) $ 638,189 Classified as: Cash equivalents $ 120,577 Marketable securities - current 438,974 Marketable securities - noncurrent 78,638 Total cash equivalents and marketable securities $ 638,189 14 Table of Contents All of the Company s marketable securities are classified as available-for-sale.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
The NDA was granted priority review by the FDA, with a Prescription Drug User Fee Act target action date in August 2026.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
In March 2025, the Company and Takeda agreed, pursuant to the provisions of the Takeda Collaboration Agreement, as amended, that Takeda would assume responsibility for leading and implementing the regulatory strategy and associated activities for preparation of the NDA related to rusfertide in PV, which was submitted to the FDA in December 2025.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: Level 1 Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
The Company operates and manages its business as one operating segment, which primarily focuses on the discovery and development of innovative medicines in areas of unmet medical need.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
All statements other than statements of historical fact, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, expectations, plans or intentions relating to clinical development, product candidates, the regulatory approval process, products and markets, and business trends and other information referred to under the sections entitled Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations, are forward-looking statements.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
o Pharmocodynamic-based target engagement in a mouse IL-17 challenge model after oral dosing.
SEC original ↗Protagonist Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Legal Proceedings 31 Item 1A.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including but not limited to geopolitical instability and changes in trade policies, including tariffs or other trade restrictions or the threat of such actions and retaliatory actions.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, outcomes, performance or achievements, or the timing of such results, outcomes, performance or achievements, to be materially different from any results, outcomes, performances or achievements expressed or implied by the forward-looking statements.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Forward-looking statements reflect our current views with respect to future events, are based on assumptions, and are subject to risks, uncertainties and other important factors, including, among other things, the potential for our programs; the timing, initiation, progress and expected results of our clinical trials and research and development programs, including enrollment, data, costs and regulatory submissions and approvals; our cash runway; our ability to advance product candidates into, and successfully complete, non-clinical studies and clinical trials; our eligibility for, and any expected benefits of, any U.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Forward-looking statements involve risks, uncertainties and assumptions that are beyond our ability to control or predict, including those risks, uncertainties and assumptions discussed in Part II, Item 1A, of this Quarterly Report, Part 1.
SEC original ↗Protagonist Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documentsEarnings releases
11 documentsPresentations
0 documentsNo presentations for Protagonist Therapeutics, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Protagonist Therapeutics, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.